Oveporexton (TAK-861)
Oveporexton (TAK-861) is a novel, orally available orexin receptor 2 (OX2R)-selective agonist developed for the treatment of Narcolepsy Type 1. Research shows it effectively restores orexin signaling in the brain, significantly improving wakefulness and reducing cataplexy.
01Dosing reference
Amount
0.5 mg to 7 mg
Frequency
Once or twice daily
Cycle
Continuous daily use
Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.
02Mechanism of action
01
OX2R Binding
Oveporexton selectively binds to and activates the orexin receptor 2 (OX2R) in the brain.
02
Orexin Signaling Restoration
It mimics the action of the naturally occurring neuropeptide orexin, which is deficient in individuals with Narcolepsy Type 1.
03
Wakefulness Promotion
This activation stabilizes the sleep-wake switch, promoting sustained wakefulness and preventing sudden transitions into REM sleep (cataplexy).
03Human evidence
Oveporexton significantly improved wakefulness, daytime sleepiness, and cataplexy frequency in patients with Narcolepsy Type 1.
Phase IIb and Phase III clinical trials evaluating the efficacy and safety of TAK-861 in NT1 patients.
The OX2R agonist oveporexton improved NT1-associated cognitive symptoms.
Secondary analysis of the TAK-861-2001 randomized clinical trial exploring effects on cognition.
04Preclinical evidence
TAK-861 induces brain-wide neuronal activation in a highly correlated manner.
Studies in orexin-tTA;TetO DTA mice models of narcolepsy.
The compound demonstrated potent wake-promoting effects and improved cataplexy-like symptoms.
Animal models of narcolepsy evaluating OX2R-selective agonists.
05What is known vs. unknown
Reasonably established
- Oveporexton is a highly selective agonist for the orexin receptor 2 (OX2R).
- It is administered orally and is designed to treat Narcolepsy Type 1 (NT1).
- Clinical trials have shown it significantly reduces excessive daytime sleepiness and cataplexy.
- It addresses the underlying pathophysiology of NT1 by replacing missing orexin signaling.
Unknowns & limits
- Long-term safety and potential for receptor desensitization with chronic use require ongoing monitoring.
- Its efficacy in other sleep disorders, such as Narcolepsy Type 2 or idiopathic hypersomnia, is still being evaluated.
06Safety & regulatory context
Regulatory statusOveporexton (TAK-861) has demonstrated a favorable safety profile in clinical trials, with common side effects including insomnia, urinary urgency, and mild gastrointestinal issues. Unlike earlier orexin agonists, it has shown a lower risk of hepatotoxicity. It recently secured regulatory approval as a first-in-class treatment for Narcolepsy Type 1 under the brand name Orzeyful.
07Compared with Modafinil
Oveporexton (TAK-861) vs. Modafinil
Key difference
Oveporexton directly targets the underlying orexin deficiency in Narcolepsy Type 1, whereas Modafinil acts as a general central nervous system stimulant.
When researchers discuss each
Researchers discuss Oveporexton as a targeted, disease-modifying therapy for NT1, while Modafinil is discussed as a traditional, broad-spectrum wakefulness-promoting agent.
08Glossary
Orexin
A neuropeptide that regulates arousal, wakefulness, and appetite, which is deficient in Narcolepsy Type 1.
Cataplexy
A sudden and transient episode of muscle weakness accompanied by full conscious awareness, typically triggered by emotions.
Agonist
A substance that initiates a physiological response when combined with a receptor.
09Knowledge check
Q1What is the primary mechanism of action of Oveporexton (TAK-861)?
Why: Oveporexton selectively stimulates the orexin receptor 2 to restore orexin signaling, which is deficient in Narcolepsy Type 1.
Q2Which of the following symptoms of Narcolepsy Type 1 does Oveporexton primarily target?
Why: Clinical trials have shown Oveporexton significantly improves wakefulness, reduces excessive daytime sleepiness, and decreases cataplexy frequency.
Q3Which uncertainty about Oveporexton is explicitly noted in the supplied dossier?
Why: The dossier's "unknownsAndLimits" explicitly states that long-term safety and the potential for receptor desensitization with chronic use require ongoing monitoring; it also says efficacy in other sleep disorders is still being evaluated, so the other options are not supported.
Q4According to the comparison in the dossier, what is the key difference between Oveporexton and Modafinil?
Why: The dossier's comparison section states that Oveporexton directly targets the underlying orexin deficiency in NT1, whereas Modafinil is described as a general, broad-spectrum wakefulness-promoting agent; the other statements contradict the dossier.
Q5Which statement about Oveporexton's regulatory status and safety profile is supported by the dossier?
Why: The dossier's "safetyAndRegulatoryContext" states that Oveporexton (TAK-861) secured regulatory approval as a first-in-class NT1 treatment under the brand Orzeyful, showed a favorable safety profile with listed common side effects, and has shown a lower risk of hepatotoxicity; the other options are not supported by the dossier.
10Sources
More in Sleep & Recovery
Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.